[go: up one dir, main page]

AR069025A1 - Un extracto de planta estandarizado, proceso para obtenerlo y usos del mismo, aislado o en una composicion farmaceutica, para prevencion, control o tratamiento de afecciones dolorosas, inflamatorias y febriles - Google Patents

Un extracto de planta estandarizado, proceso para obtenerlo y usos del mismo, aislado o en una composicion farmaceutica, para prevencion, control o tratamiento de afecciones dolorosas, inflamatorias y febriles

Info

Publication number
AR069025A1
AR069025A1 ARP080104646A ARP080104646A AR069025A1 AR 069025 A1 AR069025 A1 AR 069025A1 AR P080104646 A ARP080104646 A AR P080104646A AR P080104646 A ARP080104646 A AR P080104646A AR 069025 A1 AR069025 A1 AR 069025A1
Authority
AR
Argentina
Prior art keywords
extract
plant
standardized
pharmaceutical composition
inflammatory
Prior art date
Application number
ARP080104646A
Other languages
English (en)
Original Assignee
Eurofarma Laboratorios LTDA
Fundacao Univ Do Vale Do Itajai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurofarma Laboratorios LTDA, Fundacao Univ Do Vale Do Itajai filed Critical Eurofarma Laboratorios LTDA
Publication of AR069025A1 publication Critical patent/AR069025A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06Benzopyran radicals
    • C07H17/065Benzo[b]pyrans
    • C07H17/07Benzo[b]pyran-4-ones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Proceso de obtención de un extracto estandarizado a partir de por lo menos una parte de una planta del género Aleurites con propiedades antinociceptivas, antiinflamatorias y antipiréticas, a partir de una planta del género Aleurites. Composición farmacéutica, que comprende como ingrediente activo una cantidad farmacéuticamente eficaz de un extracto estandarizado de por lo menos una parte de una planta del género Aleurites. Por último, la presente trata de un método de tratamiento y uso de dicho extracto, aislado o en una composición farmacéutica, para prevención, control o tratamiento de afecciones dolorosas, inflamatorias y febriles. Reivindicación 1: Proceso de obtención de un extracto estandarizado caracterizado porque emplea por lo menos una parte de una planta del género Aleurites, y comprende las etapas de: (i) recolección, secado y subdivisión del material vegetal; (ii) pre-extracción; (iii) extracción con solvente extractor; (iv) filtración del extracto; (v) concentración del extracto; (vi) pasteurización; (vii) secado; y (viii) análisis cualitativo y cuantitativo (estandarización) del extracto; siendo dicho extracto estandarizado distinguido por el marcador 2’’-O-ramnosil-swertisina. Reivindicación 20: Extracto estandarizado caracterizado porque es obtenido de acuerdo con las reivindicaciones 1 a 19. Reivindicación 21: Extracto de acuerdo con la reivindicación 20, caracterizado porque contiene por lo menos un principio activo seleccionado del grupo que consiste en a-amirina, b-amirina, a-amirinona, b-amirinona, swertisina, siendo dicho extracto estandarizado en relación con su marcador 2’’-O-ramnosil-swertisina. Reivindicación 33: Composición farmacéutica de acuerdo con la reivindicación 30, caracterizada porque, adicionalmente, contiene por lo menos una sustancia farmacológicamente activa seleccionada del grupo que consiste en sustancias sintéticas, semi-sintéticas, moléculas biológicas, vitaminas y otras sustancias derivadas de origen vegetal.
ARP080104646A 2007-10-26 2008-10-24 Un extracto de planta estandarizado, proceso para obtenerlo y usos del mismo, aislado o en una composicion farmaceutica, para prevencion, control o tratamiento de afecciones dolorosas, inflamatorias y febriles AR069025A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0703947 2007-10-26

Publications (1)

Publication Number Publication Date
AR069025A1 true AR069025A1 (es) 2009-12-23

Family

ID=40580121

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104646A AR069025A1 (es) 2007-10-26 2008-10-24 Un extracto de planta estandarizado, proceso para obtenerlo y usos del mismo, aislado o en una composicion farmaceutica, para prevencion, control o tratamiento de afecciones dolorosas, inflamatorias y febriles

Country Status (8)

Country Link
US (2) US8404283B2 (es)
EP (1) EP2217257A4 (es)
AR (1) AR069025A1 (es)
CA (1) CA2703652A1 (es)
CL (1) CL2008003154A1 (es)
CO (1) CO6280404A2 (es)
MX (1) MX2010004513A (es)
WO (1) WO2009052600A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
AU2010316120B2 (en) * 2009-11-03 2013-11-21 Korea Research Institute Of Bioscience And Biotechnology Antiviral composition containing an Aleurites fordii or Daphne kiusiana extract or a fraction thereof as an active ingredient
FR3013594B1 (fr) * 2013-11-25 2017-11-10 Basf Beauty Care Solutions France Sas Utilisation cosmetique ou dermatologique d'un extrait d'aleurites moluccana
CN110483297A (zh) * 2018-05-15 2019-11-22 复旦大学 1,5-二烯型巴豆烷二萜及其在制备抗艾滋病毒药物中的用途
CN109289815B (zh) * 2018-10-24 2021-05-21 温州医科大学 一种磁性泡腾片、磁性泡腾片辅助分散固相微萃取方法、重金属检测方法及应用

Also Published As

Publication number Publication date
WO2009052600A2 (en) 2009-04-30
MX2010004513A (es) 2010-08-02
CA2703652A1 (en) 2009-04-30
CL2008003154A1 (es) 2009-10-23
CO6280404A2 (es) 2011-05-20
US8404283B2 (en) 2013-03-26
EP2217257A4 (en) 2013-06-12
EP2217257A2 (en) 2010-08-18
US20130243860A1 (en) 2013-09-19
US20100303907A1 (en) 2010-12-02
WO2009052600A3 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
Deng et al. Anxiolytic and sedative activities of Passiflora edulis f. flavicarpa
Naz et al. Antibacterial activity of Curcuma longa varieties against different strains of bacteria
Alhakmani et al. Estimation of total phenolic content, in–vitro antioxidant and anti–inflammatory activity of flowers of Moringa oleifera
Sharma et al. Green synthesis, characterization and electrochemical sensing of silymarin by ZnO nanoparticles: Experimental and DFT studies
Mamat et al. Methanol extract of Melastoma malabathricum leaves exerted antioxidant and liver protective activity in rats
Abouzed et al. Red onion scales ameliorated streptozotocin-induced diabetes and diabetic nephropathy in Wistar rats in relation to their metabolite fingerprint
Srinivasan et al. In vitro antimicrobial activity of Caesalpinia sappan L.
Rao et al. Rapid extraction of andrographolide from Andrographis paniculata Nees by three phase partitioning and determination of its antioxidant activity
Al-Saleem et al. Phytochemical standardization and biological activities of certain desert plants growing in Saudi Arabia
Alilou et al. Screening phytochimique et identification spectroscopique des flavonoïdes d’Asteriscusgraveolenssubsp. odorus
AR069025A1 (es) Un extracto de planta estandarizado, proceso para obtenerlo y usos del mismo, aislado o en una composicion farmaceutica, para prevencion, control o tratamiento de afecciones dolorosas, inflamatorias y febriles
Phansawan et al. Determination of gallic acid and rutin in extracts Cassia alata and Andrographis paniculata
Raja et al. In vitro antimicrobial activity and phytochemical analysis of Cassia auriculata Linn
Assemian et al. Garcinia mangostana leaf extracts from ivory coast possess remarkable antioxidant, anti-inflammatory, and cytotoxicological properties
Biba et al. Phytochemical analysis of Annona squamosa seed extracts
Okokon et al. Nephroprotective effect of Croton zambesicus root extract against gentimicin-induced kidney injury
Yadav et al. Anti-inflammatory activity of hydroalcoholic extract of Quisqualis indica Linn. flower in rats.
Stylianou et al. Research regarding Taraxacum officinale (L.) Weber with the intention of therapeutic exploring. Note I. Studies of phenolcarboxylic acids
Touaibia et al. Anti-inflammatory effect of Myrtus nivellei Batt & Trab (Myrtaceae) methanolic extract
Sarker et al. In vitro antioxidant, total phenolic, membrane stabilizing and antimicrobial activity of Allamanda cathartica L.: A medicinal plant of Bangladesh
Radulović et al. n-Octyl esters of long-chain fatty acids are not anthropogenic pollution markers
Ghani et al. Determination and identification of phytochemical properties of Medicago sativa L.(Alfalfa) leaf, stem and root extracts against various pathogens.
Hijazi et al. Identification of high-value bioactive constituents in Northern European willow varieties: SX Dasyclados, Endeavour, Cheviot, Tora, Resolution, S. Purpurea, Terranova, endurance
Hema et al. GC-MS study on the bioactive components and anti-cancer activities of Solanum surattense
ES2937391T3 (es) Uso cosmético, farmacéutico y nutracéutico de un extracto derivado de cultivos celulares de Cannabis sativa

Legal Events

Date Code Title Description
FB Suspension of granting procedure